VivoSeq
Psychiatry

Treatment Refractory Schizophrenia

7

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Treatment Refractory Schizophrenia is an early-stage landscape with 7 programs across 3 companies. The most active players are AbbVie, Acacia Pharma Ltd, Otsuka. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

75/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 3A

Acacia Pharma Ltd

1 program

PreclinicalOtsuka logo

Otsuka

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Terminated1 · 25%

Clinical Trials

Trial Activity

Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study
Terminated·UUniversity of Aarhus·N/A·NCT01948999·3 enrolled
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
Completed·—·Phase 3·NCT01244828·157 enrolled
Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia
Completed·VVanderbilt University·N/A·NCT00179231·80 enrolled
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
Completed·MManhattan Psychiatric Center·Phase 2/3·NCT00297947·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)